Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire, Amiens

About this trial

Acute kidney injury (AKI) is a frequent disease in conventional hospital departments and in intensive care units. It's associated with a high risk to develop chronic kidney disease (CKD), even after a single small AKI episode. It's also associated with an important morbi-mortality, particularly cardiovascular (CV). Some studies have already showed a link between AKI and CV risk but pathologic mechanisms implicated are still unknown. In AKI and CKD, numerous substances, called uremic toxins (UT) are accumulating in blood. In CKD, those toxins, and particularly Indoxyl sulfate (IS), are known to have cardiac and vascular deleterious consequences. However, in AKI, whether acute accumulation of UT may trigger CV complications is unknown.

The purpose of this study is that during AKI, a high UT concentration, in particular IS, would be associated with early vascular and cardiac dysfunctions that can be characterized by the persistence of an accelerated pulse wave velocity (PWV). The main objective is to evaluate the correlation between UT concentrations (especially IS) and arterial stiffness (PWV measurement) at three months of an AKI episode in conventional hospital departments and in the intensive care unit of nephrology.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age over 18 years old.

Patients hospitalized in conventional hospital departments and in intensive care units of nephrology.

Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis.

AKI from functional or organic aetiology

Disqualifiers

Patients with severe CKD (GFR<45ml/min/1.73 m2) or with kidney transplants.

Patients with AKI from septic or obstructive aetiology.

Patients with AKI from toxic aetiology whose toxic would be also responsable of cardia toxicity.

Patients with sepsis or blood inflammation.

Trial design

Design model

Single group

Treatments tested in this trial

  • blood sample

    Other intervention

    Blood sample withdrawal will be done and serum creatinine, IS, PCS, FGF-23, Angiopoietin-2, VCAM-1, E-Selectin and Troponin will be measured.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Change of pulse wave velocity (PWV) measurement from baseline

Time frame
at 3 months

Secondary outcomes

1

Correlation between Para-cresyl Sulfate (PCS) concentration and PWV

Time frame
3 months
2

Correlation between Fibroblast Growth Factor 23 (FGF23) concentration and PWV

Time frame
3 months
3

Correlation between Fibroblast Growth Factor 23 (FGF23) concentration and arterial pressure measurement

Time frame
3 months
4

Correlation between Fibroblast Growth Factor 23 (FGF23) concentration and cardiac diastolic function

Time frame
3 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.